Bethesda, MD, United States of America

Junichi Ishitoya

This inventor holds 1 USPTO granted patent. Top assignees: Brigham Young University, The United States of America as Represented by the Department of Health. Active years: 1997.


% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Junichi Ishitoya: Innovator in Antiviral Composition

Introduction

Junichi Ishitoya is a notable inventor based in Bethesda, MD (US). He has made significant contributions to the field of antiviral therapies. His work focuses on developing compositions that can effectively treat viral infections while minimizing adverse effects.

Latest Patents

Junichi Ishitoya holds a patent for an antiviral composition. This invention relates to a formulation that includes prostratin, a phorbol ester derivative, combined with a pharmaceutically acceptable carrier. The composition is designed to exhibit antiviral activity without substantial tumor-promoting effects or other significant toxicological properties that could hinder its use in therapy.

Career Highlights

Throughout his career, Junichi Ishitoya has worked with prominent organizations, including the United States of America as represented by the Department of Health and Brigham Young University. His research has contributed to advancements in the treatment of viral infections.

Collaborations

Some of his notable coworkers include John A. Beutler and Nancy A. Sharkey. Their collaborative efforts have furthered the understanding and development of antiviral therapies.

Conclusion

Junichi Ishitoya's innovative work in antiviral compositions highlights his commitment to improving patient outcomes in viral infections. His contributions to the field are invaluable and continue to influence future research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…